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Background: Cell lines are very useful for clinical and basic research. Thus far, only 11 reports have documented
the characteristics of ovarian endometrioid adenocarcinoma cell lines in the literature. Due to the scarcity of
information, the establishment of an ovarian malignant tumor cell line with distinctive characteristics is particularly
important to study this disease. Thus, this study was undertaken to establish and characterize a new human
endometrioid adenocarcinoma cell line of the ovary.
Methods: The cell line NOMH-1 was established from an ovarian tumor of a 44-year-old woman. Features of the
cell line studied included morphology, chromosome analysis, heterotransplantation, tumor markers, and
chemosensitivity.
Results: This cell line has been growing well for 232 months and subcultured more than 50 times. Monolayer
cultured cells were polygonal in shape, showing a pavement-like arrangement and a tendency to stack without
contact inhibition. They exhibited a human karyotype with a modal chromosomal number in the hypertriploid
range. The cells could be transplanted into the subcutis of nude mice and produced tumors resembling the
original tumor. NOMH-1 cells expressed both CEA and CA19-9 which were identified immunohistochemically in the
original tumor and the heterotransplanted tumor. The cells were sensitive to paclitaxel, an agent commonly used in
the treatment of gynecological cancers.
Conclusions: NOMH-1 is the first ovarian endometrioid adenocarcinoma cell line in which CEA and CA19-9
expression have been defined. This newly established cell line should be useful for investigating the characteristics
of ovarian endometrioid adenocarcinoma.
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Endometrioid adenocarcinoma of the ovary is a variant
of epithelial ovarian cancer and has frequent concur-
rence with endometriotic lesions. Recent studies suggest
that most endometrioid cancers arise from endome-
triosis [1,2], and they are sometimes associated with car-
cinoma of the endometrium [3]. Therefore, it was
considered important to develop an ovarian endome-
trioid adenocarcinoma cell line for clinical and basic re-
search of this disease. We describe here the establishment* Correspondence: yamatakashi@mub.biglobe.ne.jp
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reproduction in any medium, provided the orand characterization of a new human cell line (NOMH-1)
of ovarian endometrioid adenocarcinoma that express both
carcinoembryonic antigen (CEA) and CA 19–9.Methods
Patient and clinical background
On June 30, 1993, we performed an abdominal simple
total hysterectomy, bilateral salpingo-oophorectomy, and
omentectomy on a 44-year-old woman with ovarian can-
cer FIGO stage IIc (Figure 1). The patient gave informed
consent for performance of this study. Histology was
performed on the resected tissue, and the tumor was
diagnosed as an endometrioid adenocarcinoma of the
ovary by intraoperative diagnosis of frozen section.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Macroscopic appearance of the original tumor (a, b). The left ovary was a solid tumor.
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levels showed that CA 125 was 639 U/ml (normal level
<35 U/ml), CA 19–9 was 108 U/ml (<37 U/ml), and
CEA was 2.4 ng/ml (<2.5 ng/ml). The patient was trea-
ted twice with 100 mg cisplatin (CDDP) and 400 mg
etoposide (VP-16) intraperitoneally, and 5 times with
450 mg carboplatin (CBDCA), 60 mg pirarubicin hydro-
chloride (THP), and 400 mg cyclophosphamide (CPA)
intravenously. However, a follow up examination on
March 25, 1994 showed that her serum tumor markers
were increased: CA 125 was 158 U/ml, CA 19–9 was
438 U/ml, and CEA was 6.3 ng/ml. Her clinical condi-
tion deteriorated progressively because of a recurrent
abdominal tumor, and she died on October 11, 1994.Culture techniques and culture media
Tissue from the resected ovarian tumor was finely
minced with a pair of sharp blades in a dish including
serum-free Ham’s F-12 medium (Flow Laboratories Inc.,
McLean, VA), stirred slowly with a magnetic stirrer in a
0.25% trypsin solution (Flow Laboratories Inc.), centri-
fuged at 70 g for 5 min, and placed in culture medium
at 37°C in humidified 5% CO2 and 95% air. Cells were
cultured in Ham’s F-12 medium plus 20% precolostrum
newborn calf serum (Mitsubishi Chemical Industries
Ltd., Tokyo, Japan) with kanamycin. Then, subcul-
tures were passaged with 0.1% trypsin and 0.02%
ethylenediamine-tetraacetic acid (EDTA) solution
every 4 weeks. Six months after the primary culture,
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serum in the culture medium was reduced from 20%
to 10%.
Morphology of the resected original tumor and cultured
cells
Living cells grown in culture flasks were examined using
a phase contrast microscope. For histology, the original
tumor was fixed in 10% formalin, embedded in paraffin,
and 4 μm-sections were stained with hematoxylin-eosin
(HE). Monolayer cells cultured on slides were fixed in
90% ethanol and stained by Papanicolaou’s procedure
[4]. For electron microscopy, the original tumor was
fixed by immersion in a mixture of 1.25% glutaraldehyde
and 1% paraformaldehyde buffered with phosphate
saline, pH 7.4, at 4°C for 3 hr. After washing with phos-
phate buffered saline (PBS), the tumor was postfixed
with 1% osmium tetroxide at 4°C for 1 hr, then washed
in PBS, dehydrated in graded concentrations of ethanol,
and embedded in Epon 812. Sections 0.5 μm thick were
cut with a 6000 ultramicrotome (Sorvall, Du Pont, CT)
and stained with toluidine blue. Ultrathin sections exhi-
biting light gold interference color were cut from the
corresponding areas in the toluidine blue stained sec-
tions, double stained with uranyl acetate and lead citrate,
and observed under a JEM-100SX electron microscope
(JEOL, Tokyo, Japan) at 80 kV [5].
Growth characteristics
Cell characteristics were examined in passages 5–10.
Suspensions of 1 × 105 cells were plated in 35 mm plas-
tic dishes and incubated for 44 days. Then, cells from
two dishes were counted every other day by an automatic
cell counter (Coulter CounterR, Coulter Electronics, Luton,
England). The population doubling time and saturation
density were calculated from the growth curve. For studies
of plating efficiency, 1×102 and 2×102 single-suspension
cells were placed into five 60 mm plastic dishes each and
cultured for 21 days. Plating efficiency was determined by
the ratio of the number of colonies (more than 10 cells) to
the total number of inoculated cells. For the mitotic index,
monolayer cells were cultured for 5 days and treated with
1×10-7 M colcemid (Demecolcine Solution, Wako Pure
Chemical Industries, Osaka, Japan) for 4 hr, placed in a
0.2% KCl solution for 15 min, and then fixed step-by-step
in a methanol: acetic acid solution (3:1). After air-drying,
the cells were stained with Giemsa and the number of
mitotic cells in 1,000 cells were counted.
Chromosome analysis
Histograms of chromosome number distribution were
determined using 39 metaphase plates. Their karyo-
types were analyzed in 10 cells in accordance withthe International System for Human Cytogenetic
Nomenclature (ISCN 1995).
Heterotransplantation
Ten million cells (passage 10) were inoculated subcuta-
neously into the dorsal region of 6-week-old nude mice
(BALB/cAJcl-nu; Clea Japan, Inc., Tokyo, Japan). When
the tumors had grown to 5–10 mm in diameter after
4 weeks, they were removed and processed for morpho-
logical examinations. For histology, the excised tumors
were fixed in 10% formalin, embedded in paraffin, and
stained with HE. For electron microscopy, the tumors
were cut into pieces with a pair of sharp blades fixed,
stained, and observed as described above.
Tumor markers
Culture medium in which 2×106 cells / 5 ml were cul-
tured for 7 days was examined for α fetoprotein (AFP),
CA 125, CA 19–9, CA 72–4, CEA, human chorionic
gonadotropin (HCG), squamous cell carcinoma (SCC)
antigen, and tissue polypeptide antigen (TPA) by radio-
immunoassay or chemiluminescent immunoassay.
Immunohistochemical stainings
Deparaffinized sections of the original and heterotrans-
planted tumors on glass slides were immunohistochemi-
cally stained using the universal Immuno-enzyme
Polymer (UIP) method (Envision kit; DAKO, Glostrup,
Denmark). Slides were immersed in 0.03% hydrogen
peroxidase and absolute methanol to block endogenous
peroxidase, and then washed with phosphate buffered
saline and heated in an autoclave for 20 min. After cool-
ing, the slides were incubated with a primary antibody at
room temperature for 40 min and then reacted with En-
vision (DAKO) at room temperature for 30 min, fol-
lowed by incubation with diaminobenzidine (DAB)
for 5–10 min. Antibodies against CA 125 (DAKO), CA
19–9 (DAKO), CEA (DAKO), and P53 (DAKO) were
used to detect tumor markers, and against human estro-
gen receptor α (Nichirei Bioscience Inc., Tokyo, Japan)
and human progesterone receptor (Nichirei) to detect
hormone receptors.Chemosensitivity assays
The effects of actinomycin D (ACD, MSD KK, Tokyo,
Japan), doxorubicin (ADM, Kyowa Hakko Kirin Co.,
Ltd., Tokyo, Japan), 5-fluorouracil (5-FU, Kyowa Hakko
Kirin Co.), mitomycin C (MMC, Kyowa Hakko Kirin
Co.), bleomycin (BLM, Nippon Kayaku Co., Ltd., Tokyo,
Japan), vinblastine (VLB, Nippon Kayaku Co.), vincris-
tine (VCR, Nippon Kayaku Co.), carboplatin (CBDCA,
Bristol-Myers K.K., Tokyo, Japan), cisplatin (CDDP, Bristol-
Myers), etoposide (VP-16, Bristol-Myers), paclitaxel (PTX,
Figure 2 Histology of the original tumor. It shows an endometrioid adenocarcinoma stained with hematoxylin and eosin (HE).
(a,bar = 200 μm; b,bar = 50 μm).
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Shionogi & Co., Ltd., Osaka, Japan), irinotecan SN-38
(CPT-11, Yakult Honsha Co., Ltd., Tokyo, Japan) [7], and
methotrexate (MTX, Pfizer Japan Inc., Tokyo, Japan),
which are often used to treat gynecological cancers [8], on
the cultured cells were investigated by 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT)
assay. The drugs were dissolved in culture medium and
used immediately. For MTT assay, 5 x 103 cells in 100 μl
medium were seeded in tetraplicate into each well of 96-
well microwell plates. For continuous drug exposure
experiments, various diluted drugs in 50 μl were added
after 48 hr of incubation. The wells were incubated for
72 hr after the addition of drugs. MTT (50 μl of 2 mg/ml;
Wako Pure Chemical Industries, Ltd, Osaka, Japan) was
added to each well, and the plates were incubated for 4 hr.Figure 3 Phase contrast microscopy. The cells show a pavement-
like arrangement and colonies with multilayering. (bar = 200 μm).The medium was then removed, 150 μl of dimethyl sulf-
oxide (DMSO, Sigma, St. Louis, MO) was added to each
well, and the plates were agitated for 5 min. The optical
density was then read at 570 nm on a microplate reader
(Bio-Rad Laboratories, Hercules, CA) and the effective
concentration of the median lethal dose was calculated
from the dose response curve (EC50: dose of drug
required to reduce final cell number or optical density
in MTT assay to 50% of control) [9].
Results
Histopathology of the original tumor specimen
Light microscopy revealed the original tumor to be an
endometrioid adenocarcinoma, which showed tubular
glands lined by stratified non-mucin containing epithe-
lium (Figure 2).Figure 4 Cytopathology of cultured NOMH-1 cells.
Multinucleated giant cells with spindle-shaped or multipolar
cytoplasm are observed by Papanicolaou stain. (bar = 50 μm).
Figure 5 Electron micrograph of the original tumor. The cells are attached by desmosome-like junctions (a) and have abundant mitochondria
in the cytoplasm (a)(b) and numerous microvilli on the surface (b). (a,b, bar = 1 μm).
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Tissue fragments from the original tumor were cul-
tured and after a 2-month stationary period, definite
out-growths developed. Initially, contamination by
spindle-shaped fibroblasts was observed, but they
disappeared from the cultures upon passaging the
cells, which were named NOMH-1. The NOMH-1
cells grew well, without interruption, for more than
232 months, and more than 50 serial passages were
successively carried out. They continue to exhibit
stable growth.Figure 6 Growth curve of NOMH-1. The cells grew logarithmically.Morphology of the cultured cells
The cultured cells grew in monolayer and appeared to
be epithelial, showing a pavement-like arrangement.
Multilayering of cells was easily observed even before
they reached confluency (Figure 3). The cells were po-
lygonal and showed neoplastic features such as bizarre
aggregation of chromatin granules, thickened nuclear
membrane, and multiple large nucleoli. Multinucleated
giant cells were also seen (Figure 4). Electron micros-
copy revealed that adjacent cells showed desmosome-
like junctions (Figure 5a). The cells had indented nuclei
Figure 7 Distribution of chromosomal numbers in NOMH-1 (5th
generation). The modal number is in the hypertriploid range.
Figure 9 Micrograph of a tumor transplanted into a nude
mouse. It shows endometrioid adenocarcinoma closely resembling
the original tumor. (HE, bar = 50 μm).
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plasm, and numerous microvilli on the cell surface
(Figure 5b). These features suggested that the cells were
epithelial in origin.Growth characteristics
The growth curve was examined in passage 5 of the
NOMH-1 cell line. Three days after culturing, the cells
grew logarithmically (Figure 6). The population doubling
time, saturation density, plating efficiency, and mitotic
index were 273 hr, 3.7 × 104 cells/cm2, 3.6%, and 4.9%,
respectively.Chromosome analysis
This cell line had a modal chromosome number that
was in the hypertriploid range (73–80) (Figure 7).Figure 8 Karyotype of NOMH-1 (5th generation). Chromosomal analysiChromosomal analysis showed that all of the cells had
6q- and most of the cells had 8p+ (Figure 8).
Heterotransplantation
Histopathologically, the transplanted tumors were endome-
trioid adenocarcinomas that showed tubular glands lined
by stratified non-mucin containing epithelium, which
closely resembled the original tumor (Figure 9). Electron
microscopy showed desmosome-like junctions and nume-
rous microvilli as observed in the original tumor.
Tumor markers
This cell line was positive for the following tumor mar-
kers: CEA, 1,000 ng/ml; CA 19–9, 305 U/ml; CA 72–4,s showed various abnormalities.
Figure 10 Immunohistochemical stainings of the original tumor (a, c) and heterotransplanted tumor (b, d) with CEA (a, b) and CA19-9
(c, d). (a, b, c, d; bar = 100 μm).
Table 1 Chemosensitivity using a 3-(4,5-dimethylthiazol-

















EC50, effective concentration for 50% kill; PPC, peak plasma concentration
taken intravenously; ACD, actinomycin D; ADM, doxorubicin; BLM, bleomycin;
CBDCA, carboplatin; CDDP, cisplatin; CPA, 4-hydroperoxy-cyclophosphamide;
CPT-11, irinotecan hydrochloride; 5-FU, 5-fluorouracil; MMC, mitomycin C; MTX,
methotrexate; PTX, paclitaxel; VCR, vincristine; VLB, vinblastine;
VP-16, etoposide;.
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were negative for: AFP, <1 ng/ml; CA 125, 20 U/ml;
HCG, <1 mIU/ml; and SCC antigen, <0.5 ng/ml. Expres-
sion of CEA and CA 19–9 was demonstrated immuno-
histochemically in the cancer cells of the original and
heterotransplanted tumors (Figure 10). In contrast,
CA125 and P53 were negative immunohistochemically.
Hormone receptors
Neither estrogen receptor (ER) nor progesterone recep-
tor (PgR) were detected immunohistochemically in the
original and heterotransplanted tumors.
Chemosensitivity
The EC50 values of anti-cancer drugs for NOMH-1 cells
are listed in Table 1 (Figure 11).
Discussion
In this study, we established a novel cell line, NOMH-1,
of human endometrioid adenocarcinoma of the ovary by
culturing tissue fragments from a resected tumor, and to
obtain convincing evidence that this cell line truly
reflects the original tumor and disease, we investigated
its biological characteristics. We found that these cells
showed the following features: 1) viable in culture for
over 232 months; 2) neoplastic, pleomorphic, and stack
Figure 11 Dose response curve for paclitaxel. The EC50 value of paclitaxel is 5.1.
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of a human karyotype with aneuploid distribution; and
4) transplantable into nude mice and formed tumors
which histologically resembled the original tumor.
Despite the advances in culturing technology, it is still
difficult to establish a cell line, chiefly because of con-
tamination by fibroblasts, which usually grow faster than
epithelial cells and promote their detachment from the
plate. To overcome this, we took advantage of the factTable 2 Cell lines from ovarian endometrioid adenocarcinom
Cell line Age Materials Chromosome
Number
DT Transpl
#2774 (1978) - ascites 66-68 - Yes
- (1983) 47 ascites 103 (51–402) 74.4 Yes
OVK18 (1983) 49 ascites 47 (mode) 48 Yes
HMOA (1986) 57 ovarian tumor 46-47 (mode) 72,
58
Yes





HOC-I (1989) 40 recurrent
tumor
46 (44–49) 75 Yes
COV362 (1993) - - 69 (67–73) - -
SIB-1 (1994) 39 pleural
effusion
46 (43–54) - -
SNU-251 (1997) 47 ascites - 46 -
SNU-563 (1997) 54 ovarian tumor - 67 -
NOE (2007) 46 tumor fluid 65-74 - Yes
NOMH-1 44 ovarian tumor 73-80 273 Yes
DT; doubling time (hour).that fibroblasts detach faster than epithelial cells by tryp-
sin, and we removed every fibroblast and most epithelial
cells, leaving only a few colonies of epithelial cells to
grow. The cells gradually grew well to form obvious co-
lonies, and the first subculture was made 4 months after
the primary culture.
Some ovarian endometrioid adenocarcinoma cell lines
have been used for basic research, but only eleven of





- production of CA125
- CA125(−)
ER(−) ER(−), production of CA125, TPA
- -
HMFG-2, CA125 serum free medium






production of CA19-9, CEA, TPA
Yamada et al. Journal of Ovarian Research 2013, 6:8 Page 9 of 10
http://www.ovarianresearch.com/content/6/1/8line [11], OVK18 [12], HMOA [13], HNOA [13], HOC-I
[14], COV362 [15], SIB-1 [16], SNU-251 [17], SNU-563
[17], and NOE [18] ) have had their characteristics
described in detail in the literature (Table 2). Each cell
line originated from an original tumor, recurrent tumor,
ascites, pleural effusion, or tumor fluid. It seemed that
cancer cells in the fluid were more easily cultured. The
population doubling time varied greatly (28–75 hr), the
modal chromosome numbers were in the diploid range
or more, and all the cells showed karyological abnormal-
ities. Our NOMH-1 cells grew well and detached easily
after multilayering, therefore, its population doubling
time seemed longer than other cell lines.
While two previously reported cell lines were shown
to produce CA125, only one was demonstrated immu-
nohistologically. Tumor markers are useful not only in
diagnosing ovarian cancer but also in detecting tumor
recurrence or assessing therapy. In this patient, CEA
and CA19-9 were especially useful tumor markers be-
cause her serum levels were postoperatively high, which
were reproduced in the cultured cells. NOMH-1 is the
first cell line of ovarian endometrioid adenocarcinoma
which produces both CEA and CA 19–9. Therefore, it
represents a good model for the study of ovarian cancers
that express tumor markers.
The ovary is considered a target organ of steroid hor-
mones, and while NOE expresses estrogen receptor,
OVK18, HOC-I, and NOMH-1 produce neither estrogen
receptor nor progesterone receptor. As the mechanism
of action and localization of steroid hormone receptors
are still largely unknown, NOMH-1 can be used as a
non-hormone receptor cell line for studies on receptors.
Chemotherapy as well as surgery are very important
modalities for the treatment of ovarian cancer. The CAP
(CPA, ADM, CDDP) regimen had been commonly used
for treatment of ovarian epithelial carcinoma, however,
PTX and CBDCA have been recently used although they
are not always effective. Thus, CPT-11 has been used for
platinum- and taxanes-resistant epithelial ovarian cancer
[19]. In order to determine the effects of chemothera-
peutic reagents on NOMH-1 cells, chemosensitivity to a
panel of drugs was measured using the MTT assay,
which is still considered a rapid and accurate method of
screening for drug responsiveness of cultured cells. In
vitro sensitivity was defined as more than 50% growth
inhibition at peak plasma concentrations. According to
this criterion, we demonstrated that NOMH-1 cells were
sensitive to PTX only. Unfortunately, PTX could not be
used to treat the patient at that time, which reflected her
severe clinical course.
Since it is impossible to establish a cell line from the
malignant tumor of each patient, the cell line that we
established and characterized would be very useful in basic
research on ovarian cancer, especially endometrioidadenocarcinoma, the pathogenesis of which is not yet
completely known.
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